Lexaria Bioscience Corp. (NASDAQ: LEXX) announced on April 29, 2026, that it has extended its Material Transfer Agreement (MTA) with a pharmaceutical company, referred to as PharmaCO, through December 31, 2026. The original agreement was entered into on August 30, 2024, to evaluate Lexaria's DehydraTECH technology in a pre-clinical setting. The extension accommodates time for PharmaCO to receive and review Lexaria's 2026 research and development results related to GLP-1, allowing the two parties to continue their relationship under the MTA, keep the temporary exclusive license active, and contemplate additional strategic planning discussions with PharmaCO's human clinical and business development teams.
Over the past 12 months, Lexaria has advanced its GLP-1 development program, with progress reported in several 2026 R&D studies, including Human Study #7, Animal Study #1, and Animal Study #2. All studies are within the GLP-1 sector and designed to provide evidence to support potential collaboration and licensing of Lexaria's technology. These studies are fully funded with existing corporate resources, and results are expected during the third and fourth quarters of 2026.
DehydraTECH is Lexaria's patented drug delivery formulation and processing platform technology that improves oral drug delivery by increasing bio-absorption, reducing side-effects, and delivering some drugs more effectively across the blood-brain barrier. Lexaria operates a licensed in-house research laboratory and holds 65 patents granted worldwide. The extension of the MTA signals continued interest from the pharmaceutical industry in Lexaria's technology for GLP-1 drugs, which are widely used for diabetes and weight management. For more information, visit www.lexariabioscience.com.
This press release contains forward-looking statements regarding the company's ability to carry out research initiatives, receive regulatory approvals, and realize the benefits of collaborations. Factors that could cause actual results to differ include market conditions, government regulation, and scientific discovery. The original release is available at www.newmediawire.com.
